Alnylam Pharmaceuticals (ALNY) News Today

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) appears to be under slight pressure after a mixed batch of analyst updates and a regulatory headline. The stock has generally been decreased by the news flow, though HC Wainwright still kept a bullish long-term stance with a Buy rating and $510 price target.

Key investor takeaways:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to $7.86 from $7.31, suggesting stronger near-term profitability expectations for Alnylam.
• Positive Sentiment: The same analyst kept a Buy rating and reiterated a $510 price target, signaling continued confidence in Alnylam’s longer-term growth outlook.
• Positive Sentiment: HC Wainwright also lifted its Q2 2026 EPS estimate to $1.43 from $1.36, which is a modest short-term improvement.
• Neutral Sentiment: Several longer-dated earnings forecasts were mostly trimmed only slightly, including FY2027, FY2028, FY2029, and FY2030, which suggests only minor adjustments rather than a major change in the investment thesis.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 and Q4 2026 EPS estimates, which may have tempered enthusiasm around the company’s earnings trajectory.
• Negative Sentiment: An FDA untitled letter regarding Amvuttra survival claims may have added regulatory uncertainty and weighed on sentiment toward ALNY. FDA’s Untitled Letter tells Alnylam its Amvuttra survival claims don’t quite add up